Antiviral Drugs Market, by Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors and Others), by Type (Branded and Generics), by Application (HIV, Hepatitis, Herpes, Influenza, and Others),

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,500	189 Pages	Coherent Market Insights	February, 2022	CMI16970963

Best Price Guarantee
Price	from $4,500
Length	189 Pages
Publisher	Coherent Market Insights
Published Date	February, 2022
SKU	CMI16970963

Antiviral Drugs Market, by Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors and Others), by Type (Branded and Generics), by Application (HIV, Hepatitis, Herpes, Influenza, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies ), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Antiviral drugs are prescription medicine such as pills, liquid, or intravenous solution to treat HIV, hepatitis B and C viruses, influenza A and B viruses, and herpes viruses. Antiviral drugs are different from antibiotics, which fight against bacterial infections.

Furthermore, the global antiviral drugs market is driven by increasing prevalence of viral infection such as HIV/AIDS. For instance, according to the report of Joint United Nations Programme (UNAIDS) (2021), there were 37.9 million people suffering from HIV/AIDS and around 770,000 people died from this disease globally in 2020.

Market Dynamics

Key players are focusing on product approvals to strengthen their position in the global antiviral drugs market.

For instance, in April 2021, Zydus Cadila, a pharmaceutical company has received Drug Controller General of India (DCGI) approval for its antiviral drug Virafin for the treatment of moderate COVID-19 infection in adults.

Key features of the study:

This report provides in-depth analysis of the global antiviral drugs market, provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global antiviral drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include GlaxoSmithKline plc, AbbVie Inc., Merck & Co., Inc., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Cipla Inc., Aurobindo Pharma, and Gilead Sciences
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global antiviral drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antiviral drugs market

Detailed Segmentation:

Global Antiviral Drugs Market, By Drug Class:
DNA Polymerase Inhibitors
Reverse Transcriptase Inhibitors
Protease Inhibitors
Neuraminidase Inhibitors
Others
Global Antiviral Drugs Market, By Type:
Branded
Generics
Global Antiviral Drugs Market, By Application:
HIV
Hepatitis
Herpes
Influenza
Others
Global Antiviral Drugs Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Antiviral Drugs Market, By Region:
North America
By Drug Class
DNA Polymerase Inhibitors
Reverse Transcriptase Inhibitors
Protease Inhibitors
Neuraminidase Inhibitors
Others
By Type
Branded
Generics
By Application
HIV
Hepatitis
Herpes
Influenza
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
U.S.
Canada
Latin America
By Drug Class
DNA Polymerase Inhibitors
Reverse Transcriptase Inhibitors
Protease Inhibitors
Neuraminidase Inhibitors
Others
By Type
Branded
Generics
By Application
HIV
Hepatitis
Herpes
Influenza
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug Class
DNA Polymerase Inhibitors
Reverse Transcriptase Inhibitors
Protease Inhibitors
Neuraminidase Inhibitors
Others
By Type
Branded
Generics
By Application
HIV
Hepatitis
Herpes
Influenza
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Class
DNA Polymerase Inhibitors
Reverse Transcriptase Inhibitors
Protease Inhibitors
Neuraminidase Inhibitors
Others
By Type
Branded
Generics
By Application
HIV
Hepatitis
Herpes
Influenza
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Drug Class
DNA Polymerase Inhibitors
Reverse Transcriptase Inhibitors
Protease Inhibitors
Neuraminidase Inhibitors
Others
By Type
Branded
Generics
By Application
HIV
Hepatitis
Herpes
Influenza
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
GCC
Israel
Rest of Middle East
Africa
By Drug Class
DNA Polymerase Inhibitors
Reverse Transcriptase Inhibitors
Protease Inhibitors
Neuraminidase Inhibitors
Others
By Type
Branded
Generics
By Application
HIV
Hepatitis
Herpes
Influenza
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region
South Africa
Central Africa
North Africa
Company Profiles
GlaxoSmithKline plc *
Company Overview
Product Portfolio
Financial Overview
Key Highlights
Market Strategies
AbbVie Inc.
Merck & Co., Inc.
Dr. Reddy's Laboratories Ltd.
F. Hoffmann-La Roche AG
Bristol-Myers Squibb Company
Johnson & Johnson Services, Inc.
Cipla Inc.
Aurobindo Pharma
Gilead Sciences

“*” marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions: Research Objectives; Assumptions; Abbreviations
2. Market Purview: Report Description; Market Definition and Scope; Executive Summary; Market Snippet, By Drug Class; Market Snippet, By Type; Market Snippet, By Application; Market Snippet, By Distribution Channel; Market Snippet, By Region; Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis: Drivers; Restraints; Opportunity; Impact Analysis; Pipeline Analysis; Regulatory Scenario; PEST Analysis; Epidemiology; Product Launch/Approvals; Key Developments; Reimbursement Scenario
4. Global Antiviral Drugs Market – Impact of Coronavirus (Covid-19) Pandemic: COVID-19 Impact on Overall Healthcare Market; Impact Of Antiviral Drugs; Government Initiative To Combat Covid-19
5. Global Antiviral Drugs Market, By Drug Class, 2017 – 2028, (US$ Mn): Introduction; Market Share Analysis, 2021 and 2028 (%); Y-o-Y Growth Analysis, 2018 – 2028; Segment Trends; DNA Polymerase Inhibitors; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn); Reverse Transcriptase Inhibitors; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn); Protease Inhibitors; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn); Neuraminidase Inhibitors; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn); Others; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
6. Global Antiviral Drugs Market, By Type, 2017 – 2028, (US$ Mn): Introduction; Market Share Analysis, 2021 and 2028 (%); Y-o-Y Growth Analysis, 2018 – 2028; Segment Trends; Branded; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn); Generics; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
7. Global Antiviral Drugs Market, By Application, 2017 – 2028, (US$ Mn): Introduction; Market Share Analysis, 2021 and 2028 (%); Y-o-Y Growth Analysis, 2018 – 2028; Segment Trends; HIV; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn); Hepatitis; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn); Herpes; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn); Influenza; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn); Others; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
8. Global Antiviral Drugs Market, By Distribution Channel, 2017 – 2028, (US$ Mn): Introduction; Market Share Analysis, 2021 and 2028 (%); Y-o-Y Growth Analysis, 2018 – 2028; Segment Trends; Hospital Pharmacies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn); Retail Pharmacies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn); Online Pharmacies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
9. Global Antiviral Drugs Market, By Region, 2017 – 2028, (US$ Mn): Introduction; Market Share Analysis, By Region, 2021 and 2028 (%); Y-o-Y Growth Analysis, For Regions, 2017–2028; North America; Market Size and Forecast, By Drug Class, 2017 – 2028, (US$ Mn); Market Size and Forecast, By Type, 2017 – 2028, (US$ Mn); Market Size and Forecast, By Application, 2017 – 2028, (US$ Mn); Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn); Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn); U.S.; Canada; Latin America; Market Size and Forecast, By Drug Class, 2017 – 2028, (US$ Mn); Market Size and Forecast, By Type, 2017 – 2028, (US$ Mn); Market Size and Forecast, By Application, 2017 – 2028, (US$ Mn); Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn); Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn); Brazil; Mexico; Argentina; Rest of Latin America; Europe; Market Size and Forecast, By Drug Class, 2017 – 2028, (US$ Mn); Market Size and Forecast, By Type, 2017 – 2028, (US$ Mn); Market Size and Forecast, By Application, 2017 – 2028, (US$ Mn); Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn); Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn); Germany; U.K.; France; Italy; Spain; Russia; Rest of Europe; Asia Pacific; Market Size and Forecast, By Drug Class, 2017 – 2028, (US$ Mn); Market Size and Forecast, By Type, 2017 – 2028, (US$ Mn); Market Size and Forecast, By Application, 2017 – 2028, (US$ Mn); Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn); Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn); China; India; Japan; Australia; South Korea; ASEAN; Rest of Asia Pacific; Middle East; Market Size and Forecast, By Drug Class, 2017 – 2028, (US$ Mn); Market Size and Forecast, By Type, 2017 – 2028, (US$ Mn); Market Size and Forecast, By Application, 2017 – 2028, (US$ Mn); Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn); Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn); GCC; Israel; Rest of Middle East; Africa; Market Size and Forecast, By Drug Class, 2017 – 2028, (US$ Mn); Market Size and Forecast, By Type, 2017 – 2028, (US$ Mn); Market Size and Forecast, By Application, 2017 – 2028, (US$ Mn); Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn); Market Size and Forecast, By Region/Country, 2017 – 2028, (US$ Mn); South Africa; Central Africa; North Africa
10. Competitive Landscape: Competitive Snapshot; GlaxoSmithKline plc *; Company Overview; Product Portfolio; Financial Overview; Key Highlights; Market Strategies; AbbVie Inc.; Company Overview; Product Portfolio; Financial Overview; Key Highlights; Market Strategies; Merck & Co., Inc.; Company Overview; Product Portfolio; Financial Overview; Key Highlights; Market Strategies; Dr. Reddy's Laboratories Ltd.; Company Overview; Product Portfolio; Financial Overview; Key Highlights; Market Strategies; F. Hoffmann-La Roche AG; Company Overview; Product Portfolio; Financial Overview; Key Highlights; Market Strategies; Bristol-Myers Squibb Company; Company Overview; Product Portfolio; Financial Overview; Key Highlights; Market Strategies; Johnson & Johnson Services, Inc.; Company Overview; Product Portfolio; Financial Overview; Key Highlights; Market Strategies; Cipla Inc.; Company Overview; Product Portfolio; Financial Overview; Key Highlights; Market Strategies; Aurobindo Pharma; Company Overview; Product Portfolio; Financial Overview; Key Highlights; Market Strategies; Gilead Sciences; Company Overview; Product Portfolio; Financial Overview; Key Highlights; Market Strategies
11. Section: References; Research Methodology; About us and Sales Contact; *Browse 44 market data tables and 39 figures on "Antiviral Drugs Market” - Global forecast to 2028

Antiviral Therapeutics Market by Drug (Hepatitis Antiviral Drug, Herpes Antiviral Drug, HIV Antiviral Drug), Therapy (DNA Polymerase Inhibitors, Neuraminidase Inhibitors, Protease Inhibitors), Distribution - Global Forecast 2024-2030

June, 2024 | Published by: 360iResearch | USD $4,949
Global Antiviral Therapeutics Market Size Study, By Drug (Hepatitis, Herpes, HIV, Influenza), By Therapy (DNA Polymerase Inhibitors, Neuraminidase Inhibitors, Protease Inhibitors, Reverse Transcriptase Inhibitors), By Distribution Channel (Hospital Pharmacy, Independent Pharmacy & Drug Store, Online Pharmacy), and Regional Forecasts 2022-2032

July, 2024 | Published by: Bizwit Research & Consulting | USD $4,950
Antiviral Drugs Market, By Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, and Others), By Type (Branded and Generics), By Application (HIV, Hepatitis, Herpes, Influenza, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

May, 2024 | Published by: Coherent Market Insights | USD $4,500
Global Antiviral Drugs Market Size, Trends & Growth Opportunity, By Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Others), By Type (Branded, Generics), By Application, and Forecast till 2027.

December, 2022 | Published by: QualiKet Research | USD $3,950
Antiviral Drugs Market Size, Trends, Analysis, and Outlook By Type (Branded, Generics), By Class, DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Application (HIV, Hepatitis, Herpes, Influenza, Others), by Region, Country, Segment, and Companies, 2024-2030

March, 2024 | Published by: VPA Research | USD $3,980
North America HIV Drugs Market Report by Drug Class (Nucleoside Reverse Transcriptase Inhibitors, Multi-Class Combination Products, Protease Inhibitors, HIV Integrase Strand Transfer Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Entry Inhibitors—CCR5 Co-Receptor Antagonist, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and Country 2024-2032

July, 2024 | Published by: IMARC Services Pvt. Ltd. | USD $3,699

PDF E-mail From Publisher:	$4,500
Site License Fulfilled by Publisher:	$7,000
Global Site License Fulfilled by Publisher:	$10,000

Antiviral Drugs Market, by Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors and Others), by Type (Branded and Generics), by Application (HIV, Hepatitis, Herpes, Influenza, and Others),

Research Assistance

Other tasks

Antiviral Drugs Market, by Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors and Others), by Type (Branded and Generics), by Application (HIV, Hepatitis, Herpes, Influenza, and Others),

Antiviral Therapeutics Market by Drug (Hepatitis Antiviral Drug, Herpes Antiviral Drug, HIV Antiviral Drug), Therapy (DNA Polymerase Inhibitors, Neuraminidase Inhibitors, Protease Inhibitors), Distribution - Global Forecast 2024-2030

Global Antiviral Drugs Market Size, Trends & Growth Opportunity, By Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Others), By Type (Branded, Generics), By Application, and Forecast till 2027.

Research Assistance

Other tasks